There currently are no uniformly accepted clinical, neuroimaging, or laboratory outcome measures for clinical trials for the treatment of HIV associated neurocognitive disorders (HAND). The goals and objectives of this Core are: 1) to provide the resources necessary to continue a clinical cohort of well-characterized HIV+ and demographically-matched HIV- individuals for studies evaluating new outcome measures and surrogate markers for clinical trials of HAND, 2) to liaise with other NIMH Centers or other funded IPCPs involved in NeuroAIDs therapeutic work to help identify potential candidate agents, 3) to provide the resources necessary to design and conduct small pilot studies to evaluate potential novel compounds to treat HAND, 4) to maintain a data infrastructure to allow for efficient querying of clinical and laboratory data, 5) to provide statistical support for studies involving the Center Grant resources, 6) to provide a resource for linkage with ongoing Neuro-AIDS trial consortia. The Clinical Outcomes Core provides support for a cohort of 150 HIV+ and 50 HIV- individuals which is used to evaluate both neurocognitive and novel functional assessments. Stored CSF and blood specimens from cohort participants are used to validate surrogate markers. Participants with a well characterized HAND stage from the Clinical Outcomes Cohort are used for developmental projects. The Core also evaluates safety, tolerability, and efficacy outcome measures for new compounds for the treatment of HAND. Thus, the Core provides a service to develop improved outcome measures for use in clinical trials, and obtains preliminary data for candidate drugs of safety and tolerability. The Core will also obtain data to determine the sample size needed for larger, confirmatory studies of efficacy.
HIV/AIDS is a major threat to global health and urban America, and HIV-associated-neurocognitive dysfunction remains prevalent even in H/V^RT-treated people. Our research suggests that one of the drivers for this is sustained inflammation within the brain. Our Center has helped to coordinate and catalyze scientific and clinical resources at JHU to generate novel approaches to therapy.
|Sacktor, Ned; Nakasujja, Noeline; Redd, Andrew D et al. (2014) HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metab Brain Dis 29:261-8|
|Meulendyke, Kelly A; Croteau, Joshua D; Zink, M Christine (2014) HIV life cycle, innate immunity and autophagy in the central nervous system. Curr Opin HIV AIDS 9:565-71|
|Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6|
|Gamaldo, Charlene E; Gamaldo, Alyssa; McArthur, Justin C et al. (2014) Reply: To PMID 23722610. J Acquir Immune Defic Syndr 65:e124-5|
|Hulgan, Todd; Levinson, Rebecca T; Gerschenson, Mariana et al. (2014) Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. AIDS 28:1625-33|
|Yu, Ian W; Espinoza, Diego A; McAlexander, Melissa A et al. (2014) OpenArray profiling reveals no differential modulation of miRNA by positive and negative CD4+ T cell immunoselection. Exp Hematol 42:11-3|
|Figuera-Losada, Mariana; Rojas, Camilo; Slusher, Barbara S (2014) Inhibition of microglia activation as a phenotypic assay in early drug discovery. J Biomol Screen 19:17-31|
|Bora, Adriana; Ubaida Mohien, Ceereena; Chaerkady, Raghothama et al. (2014) Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. J Neurovirol 20:457-65|
|Bae, Mihyun; Patel, Neha; Xu, Haoxing et al. (2014) Activation of TRPML1 clears intraneuronal A? in preclinical models of HIV infection. J Neurosci 34:11485-503|
|Meulendyke, Kelly A; Queen, Suzanne E; Engle, Elizabeth L et al. (2014) Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 20:591-602|
Showing the most recent 10 out of 60 publications